We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

By LabMedica International staff writers
Posted on 19 Jan 2015
The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition.

Neutrophils are the most abundant (40% to 75%) type of white blood cells in mammals and form an essential part of the innate immune system. More...
These short-lived and highly motile phagocytes are formed from stem cells in the bone marrow. During the acute phase of inflammation, particularly as a result of bacterial infection, environmental exposure, and some cancers, neutrophils are one of the first-responders of inflammatory cells to migrate towards the site of inflammation. They migrate through the blood vessels, then through interstitial tissue, following chemical signals in a process called chemotaxis. Low neutrophil counts are termed neutropenia. This can be congenital, or it can develop later, as in the case of aplastic anemia or some kinds of leukemia. It can also be a side-effect of medication, most prominently chemotherapy or as the result of colonization by intracellular neutrophilic parasites. Neutropenia makes an individual highly susceptible to infections.

Fatty acid synthase is a multi-enzyme protein that catalyzes fatty acid synthesis. It is not a single enzyme but a whole enzymatic system composed of two identical 272-kDa multifunctional polypeptides, in which substrates are handed from one functional domain to the next. Its main function is to catalyze the synthesis of palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.

Since mice genetically engineered to lack the gene for FAS die in utero, effects of whole-body inhibition of lipogenesis following development have been unknown. And, as inducible global knockout of FAS (iFASKO) in mice is lethal due to a disrupted intestinal barrier and leucopenia, investigators at Washington University School of Medicine (St. Louis, MO, USA) created a line of mice where they could conditionally inactivate FAS activity.

Results published in the January 6, 2014, online edition of the journal Cell Metabolism revealed that conditional loss of FAS was associated with the selective suppression of granulopoiesis (including synthesis of neutrophils) without disrupting granulocytic differentiation. Impaired lipogenesis increased ER (endoplasmic reticulum) stress and apoptosis in neutrophils by preferentially decreasing peroxisome-derived membrane phospholipids containing ether bonds. Inhibiting ether lipid synthesis selectively constrained neutrophil development, revealing an unrecognized pathway in immunometabolism.

"So ether lipids appear to be a very precise target," said senior author Dr. Clay F. Semenkovich, professor of medicine at Washington University School of Medicine. "This may be a pathway to limit inflammation. If we could reduce the activity of these enzymes without eliminating them entirely, it could lower the levels of ether lipids and potentially help patients with leukemia and inflammatory diseases such as arthritis."

Related Links:

Washington University School of Medicine



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.